The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec ... lifetime could have implications for the treatment of acute myeloid leukemia and ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...